GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » Float Percentage Of Total Shares Outstanding

KNBIF (Kane Biotech) Float Percentage Of Total Shares Outstanding : 0.00% (As of May. 08, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Kane Biotech Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kane Biotech's float shares is 0.00 Mil. Kane Biotech's total shares outstanding is 150.26 Mil. Kane Biotech's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kane Biotech's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kane Biotech's Institutional Ownership is 0.65%.


Kane Biotech Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Kane Biotech's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/150.26
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kane Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kane Biotech Inc (OTCPK:KNBIF) » Definitions » Float Percentage Of Total Shares Outstanding
Traded in Other Exchanges
Address
290-100 Innovation Drive, Winnipeg, MB, CAN, R3T 6G2
Kane Biotech Inc is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The company has a portfolio of biotechnologies, intellectual property and products developed by its own biofilm research expertise and acquired from research institutions. The Company has a separate operating segment for its Stem Animal Health subsidiary, which operates the animal health business. The firm is also engaged in the animal health business through its Stem Animal Health subsidiary.